Hymovis® Intra-articular Injections vs Corticosteroids Intra-articular Injections in Patients Affected by Glenohumeral Osteoarthritis:

Hymovis® Intra-articular Injections vs Corticosteroids Intra-articular Injections in Patients Affected by Glenohumeral Osteoarthritis: a Monocentric Randomized Open-label Trial

This monocentric randomized open-label study aims to assess the efficacy and safety of a treatment with medium molecular weight hyaluronic acid (HA) compared to a treatment with corticosteroids on patients affected by glenohumeral osteoarthritis.

Study Overview

• Status: Completed
• Conditions: Glenohumeral Osteoarthritis
• Intervention / Treatment: Device: Hyaluronic Acid 24 MG in 3 mL Prefilled Syringe; Drug: Corticosteroid injection

Detailed Description

Glenohumeral osteoarthritis (OA) is a very common joint disease characterized by pain and functional limitation. No standardized protocols of treatment are available in clinical practice and literature data are confusing. This monocentric randomized open-label study aims to assess the efficacy and safety of a treatment with medium molecular weight hyaluronic acid (HA) compared to a treatment with corticosteroids on patients affected by glenohumeral osteoarthritis.

A total of 80 consecutive patients with glenohumeral OA (Kellegren Lawrence degree II or III) were randomized in two different groups, intto Hymovis® (24mg/3ml) (treatment group) or into corticosteroids (control group), with a follow-up after 3 and 6 months. Modifications in terms of pain (VAS), range of motion (ROM) and quality of life (EQ-5D) were observed during the treatment.

• Study Type: Interventional
• Enrollment (Actual): 80
• Phase: Phase 4

Contacts and Locations

Study Locations

• Italy
  • Rome, Italy, 00145
    • Concordia Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Male or female patient aged ≥40 years

Patient suffering from glenohumeral osteoarthritis with chronic shoulder pain. Chronic shoulder pain is defined as follows:

• Persistence for a period of at least 6 months, but not more than 5 years;
• Pain perceived by the patient with a frequency of at least 50% of the days in the month preceding the inclusion visit; Kellgren-Lawrence grade of 2 or 3 in the glenohumeral joint confirmed by x-ray exam performed within 3 months prior to the inclusion visit.

Presence, at baseline, of pain on movement, in the shoulder under study, measured by VAS with a score between 40 and 80 mm Presence at baseline of pain in the contralateral shoulder at least 10mm less than the study shoulder and no more than 40mm as measured by VAS at the inclusion visit

Presence, at baseline, of limitation of shoulder motion in at least one direction in the following ranges of motion:

• Fixed scapula abduction ≤ 80°
• Internal rotation in abduction ≤ 55°
• External rotation in abduction ≤ 80° These shoulder limitations are for normal expected excursions. Patient who has not responded adequately to non-pharmacological conservative therapy and to taking simple analgesics Patient willing to sign and able to understand the Informed Consent form Patient who is not pregnant or nursing. Women of childbearing potential (including women who have been less than one year postmenopausal) must agree to use reliable contraception for the duration of the study.

Exclusion Criteria:

• Presence, on clinical evaluation, of adhesive capsulitis
• Evidence of rotator cuff injury
• Presence of primary extra-articular shoulder syndromes (eg impingement, bursitis, tendonitis)
• Evidence of clinically significant shoulder deformity
• Signs, evident on X-ray radiography of the shoulder, of recent fractures, severe loss of bone density and/or severe deformity
• Diagnosed with crystal deposition disease of calcium pyrophosphate dihydrate (CPPD) or chondrocalcinosis of the shoulder
• Presence of pathology of the cervical vertebrae (able to alter the clinical evaluation) which, in the three months preceding the inclusion visit, was symptomatic and required active treatment
• Presence of any active musculoskeletal disease affecting the diagnosis/evaluation of shoulder pain or presence of pain of any neurological etiology and acute shoulder infection
• Presence of major surgery, arthroplasty or arthroscopy in the shoulder under study in the 6 months prior to inclusion and/or surgery planned during the study
• Patient undergoing local radiotherapy for breast cancer
• Patient with polymyalgia rheumatica
• History of skin cancer (except basal cell carcinoma) treated for less than two years
• History of severe recurrent or immune-mediated allergic reactions
• Presence of infection and/or skin pathologies in the injection area; psoriasis
• Presence of serious gastrointestinal, renal, hepatic, pulmonary, cardiovascular, neurological disorders that could interfere with the study results or patient's inability to comply with the study requirements
• Known allergy or suspected allergic reactions to hyaluronate or corticosteroid preparations
• Taking HA products intra-articularly in the month preceding the inclusion visit
• Taking bisphosphonates and/or pharmaceutical products taken orally and containing glucosamine and/or chondroitin sulphate and/or diacerin (eg Chondrosulf, Structum 500, Dona, Viatril, Fisiodar, Artrodar, etc.) in the month preceding the inclusion visit unless the dosage was stable in the two months prior to the inclusion visit
• Intra-articular corticosteroid injections in the study shoulder in the three months preceding the inclusion visit
• Intra-articular corticosteroid injections in any joint in the month preceding the inclusion
• Taking oral corticosteroids in the month prior to the inclusion visit (only inhaled corticosteroids are permitted)
• Previous use of HA in the study shoulder within 6 months prior to inclusion
• Changed physical therapy in the month prior to inclusion visit or unwillingness to maintain stable regimen
• Patient with history of thyroid insufficiency
• Patient being treated with anticoagulant therapy
• Patient on phenobarbital treatment prior to study inclusion
• Taking analgesic therapies (NSAIDs, opioid analgesics, topical analgesics) for any condition that could interfere with the evaluation of the shoulder under study
• Intake of another experimental product in the month preceding the inclusion visit
• Patient who, in the opinion of the investigator, is unwilling to comply with study procedures or will not cooperate during the course of the study
• Pregnant or breastfeeding woman

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment group; patients shoulder treated with Hymovis® 24mg/3ml.	Device: Hyaluronic Acid 24 MG in 3 mL Prefilled Syringe; Patients in the treatment group received two intra-articular injections with Hymovis® (24mg/3ml) a week apart from each other
Active Comparator: Control group; patients shoulder treated with Corticosteroid.	Drug: Corticosteroid injection; Patients in control group received two intra-articular injections with corticosteroids a week apart from each other.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the pain reduction in the target shoulder compared to control group	Changes of pain on movement in the target shoulder, evaluated with a 0-100 mm Visual Analogue Scale (VAS) values compared to baseline (V1).	At 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the Quality of Life of the patients	Changes of patient's quality of life, evaluated by administration of the EuroQol 5-Dimension Questionnaire (EQ-5D-5L) compared to baseline (V1)	At 6 months
Evaluate the amelioration of shoulder functionality	Clinical functional assessment on movement from baseline (V1), measured by Constant Murley (CMS) shoulder test ;	At 6 months
Evaluate the pain reduction in the target shoulder compared to baseline	Changes of pain on movement in the target shoulder, evaluated with a 0-100 mm Visual Analogue Scale (VAS) values compared to baseline (V1).	At 6 months
Evaluation of the safety of the treatment	Safety of Hymovis® were evaluated in terms of incidence of treatment-emergent adverse events (TEAEs) over the investigational period.	12 months

Collaborators and Investigators

• Sponsor: Concordia Hospital Rome

Study record dates

Study Major Dates

• Study Start (Actual): May 2, 2021
• Primary Completion (Actual): November 10, 2021
• Study Completion (Actual): March 31, 2022

Study Registration Dates

• First Submitted: August 29, 2023
• First Submitted That Met QC Criteria: September 12, 2023
• First Posted (Actual): September 21, 2023

Study Record Updates

• Last Update Posted (Actual): September 21, 2023
• Last Update Submitted That Met QC Criteria: September 12, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: Osteoarthritis; Hyaluronic Acid; Corticosteroids
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Physiological Effects of Drugs; Immunologic Factors; Protective Agents; Adjuvants, Immunologic; Viscosupplements; Hyaluronic Acid
• Other Study ID Numbers: Hymovis 10-04-21

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No